← Russell 3000 cross-section

BIOA BioAge Labs, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$454m
Revenue TTM
$10m
Net income TTM
$-94m
Free cash flow
$-88m
Composite score
Sector rank
#2437

Valuation

P / E
EV / EBITDA
EV / sales
13.0
FCF yield
-19.42%
Earnings yield vs 10-yr
-25.56pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-912.2%
EBITDA margin
ROE
-25.2%
ROIC
-189.2%
Revenue growth

Insider activity, last 90 days

Net open-market
$-1.58m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For example, we are party to the Sales Agreement with Leerink relating to the sale and issuance, from time to time, of shares of our common stock in at-the-market equity offerings with an aggregate offering price up to $75.0 million.BioAge Labs, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →